| Literature DB >> 30244034 |
Yimei Cao1, Wei Zhou2, Xiangchuan Xing2, Jing Zhang3, Yuanfang Fu3, Kun Li3, Pu Sun3, Pinghua Li3, Xingwen Bai3, Xueqing Ma3, Huifang Bao3, Dong Li3, Yingli Chen3, Zengjun Lu4, Zaixin Liu5.
Abstract
Foot-and-mouth disease (FMD) is a devastating animal disease. A previously developed multi-epitope protein B4 vaccine of the FMD virus (FMDV) serotype O provides safety advantages over inactivated vaccines and could be used to prevent and control FMD in pigs. Commercial enzyme-linked immunosorbent assay (ELISA) kits for assessing vaccine efficacy are available for the inactivated vaccines but not for the multi-epitope protein vaccine. In this study, multi-epitope protein B4 was expressed in Escherichia coli, and an indirect ELISA (I-ELISA) was developed to detect antibodies against FMDV serotype O in pigs. The specificity and sensitivity were 96.7% and 95.9%, respectively. B4-vaccinated pigs yielded B4 I-ELISA serum values that were positively correlated with clinical protection against challenge with FMDV serotype O. The I-ELISA's ability to detect antibodies from animals vaccinated with the inactivated vaccine was also evaluated, and the B4 I-ELISA values were significantly positively correlated with liquid-phase blocking ELISA (LPBE) titers (r = 0.6708, p < 0.0001); thus, the I-ELISA was also suitable for detection of antibodies from swine vaccinated with the inactivated vaccine.Entities:
Keywords: FMD; I-ELISA; Multi-epitope protein B4; Pig
Mesh:
Substances:
Year: 2018 PMID: 30244034 DOI: 10.1016/j.jviromet.2018.09.008
Source DB: PubMed Journal: J Virol Methods ISSN: 0166-0934 Impact factor: 2.014